Upregulation of Twist2 in Non-Muscle Invasive Urothelial Carcinoma of the Bladder Correlate with Response to Treatment and Progression
DOI:
https://doi.org/10.3889/oamjms.2018.165Keywords:
Bladder cancer, Epithelial-mesenchymal transition, Twist2, NMIBC, BCGAbstract
BACKGROUND: Twist2 is a transcription factor and an epithelial-to-mesenchymal transition that plays an important role in cell polarity, cell adhesion, and has a role in tumour invasion and metastases.
AIM: In this study, we examined the expression of Twist2 in non-muscle invasive bladder carcinoma (NMIBC) and correlated the expression with response to treatment and tumour progression.
METHODS: Data of 305 patients with NMIBC of Ta, T1 were retrieved from hospitals archives. Twist2 expression was examined in tissue samples by immunohistochemistry at initial diagnosis and final follow-up, normal control was 10 normal urothelium, 10 patients with muscle-invasive bladder cancer (MIBC) were a positive control. Treatment of NMIBC was implemented according to the European Association of Urology guidelines on NMIBC. The descriptive statistical analysis included means, standard deviation, p-value; Univariate and multivariate Cox regression analyses.
RESULTS: Twist2 expression score was identified as negative, low (1-15%); medium (15-40%); and high (40-100%). Patients who had low or low medium scores at the initial diagnosis had a good response and a favourable prognosis. Expression of a high score of Twist2 in patients having high-grade T1 tumours showed non-responsiveness to repeated courses of intravesical bacillus Calmette Guerin (BCG) therapy and was upstaged to MIBC.
CONCLUSION: Twist2 expression in tissue samples of NMIBC would indicate the tumour response to therapy, upgrading and upstaging in the follow up after intravesical BCG therapy.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Yun SJ, Kim WJ. Role of the epithelial-mesenchymal transition in bladder cancer: from prognosis to therapeutic target. Korean J Urol. 2013; 54(10):645-650. https://doi.org/10.4111/kju.2013.54.10.645 PMid:24175036 PMCid:PMC3806986
Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest.2009; 119: 1420–1428. https://doi.org/10.1172/JCI39104 PMid:19487818 PMCid:PMC2689101
Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell.2009; 139: 871–890. https://doi.org/10.1016/j.cell.2009.11.007 PMid:19945376
Klymkowsky MW, Savagner P. Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. Am J Pathol. 2009; 174: 1588–1593. https://doi.org/10.2353/ajpath.2009.080545 PMid:19342369 PMCid:PMC2671246
Mao Y, Zhang N, Xu J, Ding Z, Zong R, Liu Z. Significance of heterogeneous Twist2 expression in human breast cancers. PLoS One. 2012; 7(10):e48178. https://doi.org/10.1371/journal.pone.0048178 PMid:23133563 PMCid:PMC3485060
Singh R, Ansari JA, Maurya N, Mandhani A, Agrawal V, Garg M. Epithelial-To-Mesenchymal Transition and Its Correlation with Clinicopathologic Features in Patients with Urothelial Carcinoma of the Bladder. Clin Genitourin Cancer. 2016. pii: S1558-7673(16)30224-5.
Liu B, Miyake H, Nishikawa M, Fujisawa M. Expression profile of epithelial-mesenchymal transition markers in non–muscle-invasive urothelial carcinoma of the bladder: Correlation with intravesical recurrence following transurethral resection. InUrologic Oncology: Seminars and Original Investigations. 2015; 33(3):110-e11. https://doi.org/10.1016/j.urolonc.2014.08.012
Zhao J , Dong D, Sun L, Zhang G, Sun L. Prognostic significance of the epithelial-to-mesenchymal transition markers e-cadherin, vimentin and twist in bladder cancer. Int Braz J Urol. 2014; 40(2):179-89. https://doi.org/10.1590/S1677-5538.IBJU.2014.02.07 PMid:24856504
Wallerand H, Robert G, Pasticier G, Ravaud A, Ballanger P, Reiter RE, Ferrière JM. The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers. Urol Oncol. 2010; 28(5):473-9. https://doi.org/10.1016/j.urolonc.2008.12.018 PMid:19272800
Li X, Yang J, Wang X, Li X, Liang J, Xing H. Role of TWIST2, E-cadherin and Vimentin in epithelial ovarian carcinogenesis and prognosis and their interaction in cancer progression. Eur J Gynaecol Oncol. 2016; 37(1):100-8. PMid:27048119
Galván JA , Helbling M , Koelzer VH, et al. TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer. Oncotarget. 2015; 6(2):874-85.12.
Wang T, Li Y, Wang W, et al. Twist2, the key Twist isoform related to prognosis, promotes invasion of cervical cancer by inducing epithelial-mesenchymal transition and blocking senescence. Hum Pathol. 2014; 45(9):1839-46. https://doi.org/10.1016/j.humpath.2014.05.001 PMid:24974259
Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, van Rhijn BW. EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: update 2016. European urology. 2017; 71(3):447-61. https://doi.org/10.1016/j.eururo.2016.05.041 PMid:27324428
Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 1994; 86(11):829-35. https://doi.org/10.1093/jnci/86.11.829 PMid:8182763
Keegan PE, Matthews JN, Lunec J, Neal DE. Statistical problems with 'optimal' thresholds in studies of new prognostic factors in urology. BJU Int. 2000; 85(4):392-7. https://doi.org/10.1046/j.1464-410x.2000.00491.x PMid:10691812
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
